NEWS
Our Latest News
ARCHIMED acquires cell line development pioneer ExcellGene to accelerate expansion into biosimilars and high-performance transfection solutions
Global private equity healthcare specialist ARCHIMED acquires a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting (both in the biologic therapeutics sector), partnering with founders and management, to create a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins, and other advanced therapeutics.
ARCHIMED’s NAMSA consolidates leadership in Medical Device Clinical Research, buying Clinlogix
August
2,
2021
ARCHIMED buys Stragen Pharma, a leader in the development, registration and distribution of hard-to-make generic drugs
June
24,
2021
ARCHIMED’s Fytexia buys B Natural, the European leader in the extraction and refinement of compounds produced by bees
June
1,
2021
ARCHIMED’s Direct Healthcare Group buys United Care BV
March
24,
2021
ARCHIMED’s Direct Healthcare Group acquires Talley
March
3,
2021
368